EGRX - Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman | Benzinga

SAN FRANCISCO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investors who suffered substantial losses to submit your losses now.

Class Period: Aug. 8, 2023 – Nov. 28, 2023
Lead Plaintiff Deadline: Feb. 9, 2024
Visit: www.hbsslaw.com/investor-fraud/EGRX
Contact An Attorney Now: EGRX@hbsslaw.com
                                           844-916-0895

Eagle Pharmaceuticals, Inc. (EGRX) Securities Fraud Class Action:

On Dec. 15, 2023, one month after telling the market about improper accounting in Q3 2023, Eagle disclosed that investors should now no longer rely on its financial statements for 2Q 2023 as well.

The company revealed that 2Q 2023 reserves and price adjustments recorded for its lung cancer drug PEMFEXY® should have been higher, and therefore its net product sales for the period were correspondingly overstated. The company also stated that its failure to deliver its financial statements to its lenders constituted an event of default ...

EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman>Full story available on Benzinga.com